Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 20/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 18/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23000656 | 1.00 | MAPKAPK5 (0.64) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751356 | 0.94 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25783441 | 0.93 | MAPKAPK5 (0.64) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461734 | 0.93 | MAPKAPK5 (0.63) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461613 | 0.92 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461611 | 0.92 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL29215942 | 0.92 | MAPKAPK5 (0.55) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25783513 | 0.92 | MAPKAPK5 (0.63) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461592 | 0.91 | MAPKAPK5 (0.61) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461594 | 0.91 | MAPKAPK5 (0.61) | MAPKAPK5MAPK14MAPK1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119454711-A | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119053588-A | P38 alpha-MK 2 inhibitor compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-115484952-B | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-116178345-B | Substituted pyrimidinyl-pyridinyl-pyridone compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4313970-A1 | MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4247380-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116685322-A | Method for synthesizing substituted pyridone-pyridyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116425722-A | Substituted bipyridone-aryl (hetero) ring compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116396274-A | Substituted bipyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116178345-A | Substituted pyrimidinyl-pyridinyl-pyridone compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4125891-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115484952-A | Methods, compositions, and crystalline forms of substituted pyridone-pyridyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022212489-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022109481-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |